+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Carbapenem"

Antibiotic Drug Resistance. Edition No. 1 - Product Thumbnail Image

Antibiotic Drug Resistance. Edition No. 1

  • Book
  • October 2019
  • 720 Pages
Antimicrobial Resistance in Agriculture. Perspective, Policy and Mitigation - Product Thumbnail Image

Antimicrobial Resistance in Agriculture. Perspective, Policy and Mitigation

  • Book
  • September 2019
Antibiotics and Antimicrobial Resistance Genes in the Environment. Volume 1 in the Advances in Environmental Pollution Research series. Advances in Pollution Research - Product Thumbnail Image

Antibiotics and Antimicrobial Resistance Genes in the Environment. Volume 1 in the Advances in Environmental Pollution Research series. Advances in Pollution Research

  • Book
  • November 2019
Loading Indicator

The Carbapenem market is a subset of the Antibiotics market, which is composed of drugs used to treat bacterial infections. Carbapenems are a class of antibiotics that are used to treat serious infections caused by bacteria that are resistant to other antibiotics. They are typically used as a last resort when other antibiotics have failed. Carbapenems are generally well-tolerated and have a low risk of side effects. Carbapenems are used to treat a wide range of infections, including pneumonia, urinary tract infections, and skin and soft tissue infections. They are also used to treat infections caused by multidrug-resistant bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA). The Carbapenem market is highly competitive, with several major players. These include Merck & Co., Pfizer, GlaxoSmithKline, AstraZeneca, and Sanofi. Other companies in the market include Allergan, Novartis, and Daiichi Sankyo. Show Less Read more